Another advantage is that nanoparticles themselves can be conjugated to aptamers for targeted delivery; Gonzalez-Valdivieso and colleagues devised a docetaxel and AKT peptide inhibitor recombinant fusion-containing elastin-like recombinamer (ELR) vehicle, which was conjugated to a DNA aptamer that specifically recognizes the tumor marker, CD44, to selectively target colorectal cancer cells [418]. This evidence concerns the gene CD44 and neoplasm.